Drug Profile


Alternative Names: SK 1405

Latest Information Update: 04 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanwa Kagaku Kenkyusho
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pruritus

Most Recent Events

  • 19 Jul 2017 Sanwa Kagaku Kenkyusho plans a phase II trial for Pruritus (NCT03218501)
  • 01 Jul 2016 Sanwa Kagaku Kenkyusho initiates a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (PO) (NCT02846181)
  • 10 Apr 2016 Sanwa Kagaku Kenkyusho completes a phase I trial for Pruritus (In healthy volunteers) in United Kingdom (NCT02650076)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top